During the last session, Janux Therapeutics Inc (NASDAQ:JANX)’s traded shares were 0.66 million, with the beta value of the company hitting 3.23. At the end of the trading day, the stock’s price was $53.92, reflecting an intraday gain of 1.28% or $0.68. The 52-week high for the JANX share is $71.71, that puts it down -32.99 from that peak though still a striking 85.55% gain since the share price plummeted to a 52-week low of $7.79. The company’s market capitalization is $3.12B, and the average intraday trading volume over the past 10 days was 0.75 million shares, and the average trade volume was 974.76K shares over the past three months.
Janux Therapeutics Inc (JANX) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.25. JANX has a Sell rating from 0 analyst(s) out of 3 analysts who have looked at this stock. 1 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 2 recommend a Buy rating for it.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Janux Therapeutics Inc (NASDAQ:JANX) trade information
Janux Therapeutics Inc (JANX) registered a 1.28% upside in the last session and has traded in the red over the past 5 sessions. The stock spiked 1.28% in intraday trading to $53.92, hitting a weekly high. The stock’s 5-day price performance is -2.27%, and it has moved by -9.92% in 30 days. Based on these gigs, the overall price performance for the year is 423.50%. The short interest in Janux Therapeutics Inc (NASDAQ:JANX) is 6.41 million shares and it means that shorts have 4.32 day(s) to cover.
The consensus price target of analysts on Wall Street is $69.5, which implies an increase of 22.42% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $42 and $100 respectively. As a result, JANX is trading at a discount of -85.46% off the target high and 22.11% off the low.
Janux Therapeutics Inc (JANX) estimates and forecasts
Statistics show that Janux Therapeutics Inc has underperformed its competitors in share price, compared to the industry in which it operates. Janux Therapeutics Inc (JANX) shares have gone up 35.14% during the last six months, with a year-to-date growth rate less than the industry average at -4.55% against 16.80.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings shrunk an estimated -92.62%. While earnings are projected to return -7.68% in 2025.
JANX Dividends
Janux Therapeutics Inc is due to release its next quarterly earnings in February. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Janux Therapeutics Inc (NASDAQ:JANX)’s Major holders
Janux Therapeutics Inc insiders own 6.94% of total outstanding shares while institutional holders control 86.25%, with the float percentage being 92.68%. RA CAPITAL MANAGEMENT, L.P. is the largest shareholder of the company, while 238.0 institutions own stock in it. As of 2024-06-30, the company held over 9.17 million shares (or 18.6864% of all shares), a total value of $383.95 million in shares.
The next largest institutional holding, with 7.78 million shares, is of FMR LLC’s that is approximately 15.8566% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $325.8 million.
